Search clinical trials for: branaplam

Total 2 results

Novartis Pharmaceuticals

Completed

An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy

Belgium, Germany, Italy, Russian Federation, Poland, Bulgaria, Denmark
Novartis Pharmaceuticals

Completed

A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease (VIBRANT-HD)

Early Manifest Huntington Disease

Canada, Germany, France, Spain, Hungary

3

Subscribe